Cliff Asness’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-444,467
| Closed | -$9.53M | – | 3915 |
|
|
2026
Q1 | $9.53M | Buy |
444,467
+12,709
| +3% | +$179K | ﹤0.01% | 1363 |
|
|
2025
Q4 | $4.02M | Buy |
431,758
+323,281
| +298% | +$2.7M | ﹤0.01% | 1704 |
|
|
2025
Q3 | $765K | Sell |
108,477
-171,373
| -61% | -$1.18M | ﹤0.01% | 2585 |
|
|
2025
Q2 | $1.82M | Sell |
279,850
-338,777
| -55% | -$2.33M | ﹤0.01% | 1836 |
|
|
2025
Q1 | $4.91M | Buy |
618,627
+530,429
| +601% | +$5.71M | 0.01% | 1132 |
|
|
2024
Q4 | $1.12M | Sell |
88,198
-42,112
| -32% | -$586K | ﹤0.01% | 1830 |
|
|
2024
Q3 | $1.82M | Buy |
130,310
+17,290
| +15% | +$247K | ﹤0.01% | 1553 |
|
|
2024
Q2 | $1.56M | Buy |
113,020
+94,703
| +517% | +$1.39M | ﹤0.01% | 1564 |
|
|
2024
Q1 | $303K | Buy |
18,317
+8,159
| +80% | +$122K | ﹤0.01% | 2130 |
|
|
2023
Q4 | $148K | Buy |
+10,158
| New | +$123K | ﹤0.01% | 2251 |
|
|
2023
Q3 | – | Sell |
-14,404
| Closed | -$172K | – | 2329 |
|
|
2023
Q2 | $172K | Buy |
14,404
+1,348
| +10% | +$17.6K | ﹤0.01% | 2099 |
|
|
2023
Q1 | $175K | Buy |
13,056
+3,545
| +37% | +$69.2K | ﹤0.01% | 2071 |
|
|
2022
Q4 | $205K | Buy |
+9,511
| New | +$195K | ﹤0.01% | 2076 |
|
Other funds holding DAWN
Cliff Asness's DAWN Position: Q2 2026 in Review
Cliff Asness sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 444,467 shares — an estimated $9.53M sold.
Cliff Asness first reported a position in DAWN in Q4 2022 and held it in 13 quarters. The position peaked at $9.53M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Cliff Asness reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Cliff Asness sold 444,467 Day One Biopharmaceuticals shares in Q2 2026, an estimated $9.53M.
- Cliff Asness first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 13 quarters.
- Cliff Asness's Day One Biopharmaceuticals position peaked at $9.53M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.